Pharmaceutical manufacturer focused on infertility, multiple sclerosis, and oncology
EMD Serono manufactures therapeutics for infertility, multiple sclerosis, and cancer — areas with significant unmet medical need. The company runs a hybrid commercial and research operation: strong hiring velocity in healthcare and sales roles reflects aggressive market expansion efforts, while the technical stack spans clinical-grade sequencing tools (Illumina, PacBio, Nanopore, GATK, BLAST) and computational biology platforms (Nextflow, AlphaFold, ProteinMPNN), indicating active drug discovery and development work. Pain-point clustering around prescriber expansion and channel throughput suggests the primary friction is sales execution and market access, not R&D capacity.
Notable leadership hires: Scientific Director, Clinical Trial Lead, Translational Research Lead, Channel Analytics Lead, Business Director
EMD Serono is the U.S. and Canadian healthcare division of Merck KGaA, a company with over 350 years of history. The organization employs approximately 1,100 people across the United States, with commercial, clinical, and research operations centered in Massachusetts. The product portfolio addresses difficult-to-treat conditions: fertility treatments (including Pergoveris), multiple sclerosis therapies, and oncology solutions. Current initiatives include brand strategy rollout, prescriber network expansion, payer optimization, and real-world evidence studies to support market access and clinical positioning.
EMD Serono uses SAP and Ariba for enterprise resource planning, sequencing platforms (Illumina, PacBio, Nanopore), bioinformatics tools (GATK, BLAST, Nextflow), computational biology (AlphaFold, ProteinMPNN), and analytics (Snowflake, Redshift, Tableau, R, Python).
Boston, Massachusetts. The company operates commercial, clinical, and research facilities across the U.S., and is actively hiring in Peru as well.
Other companies in the same industry, closest in size